Dodamani Manjunath Havalappa, Lila Anurag Ranjan, Memon Saba Samad, Sarathi Vijaya, Arya Sneha, Rane Ankita, Sehemby Manjeet Kaur, Garg Robin, Bhandare Vishwambhar Vishnu, Karlekar Manjiri, Patil Virendra A, Kunwar Ambarish, Bandgar Tushar R
Department of Endocrinology, Seth G.S Medical College & KEM Hospital, Parel, Mumbai, Maharashtra, 4000012, India.
Department of Endocrinology, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, Karnataka, India.
Calcif Tissue Int. 2023 Apr;112(4):483-492. doi: 10.1007/s00223-023-01061-8. Epub 2023 Jan 27.
Alopecia in hereditary vitamin D resistant rickets (HVDRR) has some correlation with severe rickets and poor overall response. However, these observations are based on small series. Hence, we aim to assess the genotypic spectrum of HVDRR and its correlation with alopecia and clinical response. Seven genetically-proven HVDDR patients from five unrelated families and 119 probands from systematic review were analysed retrospectively for phenotypic and genotypic data and overall response to therapy. In our cohort mean age at rickets onset was 12 (± 3.4) months. Alopecia was present in all patients but one. All patients had poor overall response to oral high-dose calcium and calcitriol and most required intravenous calcium. Genetic analyses revealed four novel variants. On systematic review, alopecia was present in majority (81.5%) and preceded the onset of rickets. Patients with alopecia had higher serum calcium (7.6 vs.6.9 mg/dl, p = 0.008), lower 1, 25(OH) D (200 vs.320 pg/ml, p = 0.03) and similar overall response to oral therapy (28.7% vs. 35.3%, p = 0.56). Alopecia was present in 51.4% of non-truncating (NT) ligand-binding domain (LBD) variants, whereas it was universal in truncating LBD and all DNA binding-domain (DBD) variants. Overall response to oral therapy was highest in LBD-NT (46.4%) as compared to 7.6% in LBD-truncating and 19% in DBD-NT variants. Among LBD-NT variants, those affecting RXR heterodimerization, but not those affecting ligand affinity, were associated with alopecia. Both alopecia and overall response have genotypic correlation. Age at diagnosis and overall response to oral therapy were similar between patients with and without alopecia in genetically proven HVDRR.
遗传性维生素D抵抗性佝偻病(HVDRR)中的脱发与严重佝偻病及总体反应不佳存在一定关联。然而,这些观察结果基于小样本系列。因此,我们旨在评估HVDRR的基因型谱及其与脱发和临床反应的相关性。对来自五个无关家庭的7例经基因证实的HVDDR患者以及系统综述中的119例先证者进行回顾性分析,以获取表型和基因型数据以及对治疗的总体反应。在我们的队列中,佝偻病发病的平均年龄为12(±3.4)个月。除1例患者外,所有患者均有脱发。所有患者对口服高剂量钙和骨化三醇的总体反应不佳,大多数需要静脉补钙。基因分析发现了四个新变体。经系统综述,大多数患者(81.5%)存在脱发,且脱发先于佝偻病发病。有脱发的患者血清钙水平较高(7.6 vs.6.9mg/dl,p = 0.008),1,25(OH)D水平较低(200 vs.320pg/ml,p = 0.03),对口服治疗的总体反应相似(28.7% vs. 35.3%,p = 0.56)。51.4%的非截短(NT)配体结合域(LBD)变体存在脱发,而截短LBD和所有DNA结合域(DBD)变体中脱发普遍存在。与LBD截短变体中的7.6%和DBD-NT变体中的19%相比,LBD-NT变体对口服治疗的总体反应最高(46.4%)。在LBD-NT变体中,影响RXR异二聚化但不影响配体亲和力的变体与脱发有关。脱发和总体反应均与基因型相关。在经基因证实的HVDRR患者中,有脱发和无脱发患者的诊断年龄及对口服治疗的总体反应相似。